Mr. Peter Halling is President & Chief Executive Officer of ALK-Abelló A/S from 2023. Mr. Peter Halling served as Chief Executive Officer at Fertin Pharma A/S since August 2020. He has an extensive experie...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Claus Solje	Executive VP	1.5yrs	DKK 14.86m	Veri yok
Søren Niegel	Executive VP of Commercial Operations & Member of Management Board	12.6yrs	DKK 6.51m	0.036% DKK 12.8m
Henriette Mersebach	Executive VP Research & Development & Member of Management Board	1.8yrs	DKK 7.18m	Veri yok
Katja Thalund	Project Director of Global CMC Development & Employee-elected Director	no data	DKK 350.00k	Veri yok
Lise Maerkedahl	Project Director of Global Research & Employee-elected Director	no data	DKK 270.00k	Veri yok
Peter Halling	President & CEO	1.9yrs	Veri yok	Veri yok
Per Plotnikof	VP of Corporate Communications	no data	Veri yok	Veri yok
Jacob Glenting	Senior Vice President of Global Strategy & Corporate Development	less than a year	Veri yok	Veri yok
Lika Thiesen	Executive Vice President of Global People & Organisation	less than a year	Veri yok	Veri yok
Hendrik Kees Nolte	Senior Vice President of Research & Development - North America and International Markets	7.8yrs	Veri yok	Veri yok
Christian Houghton	Executive Vice President of Product Supply	5.9yrs	Veri yok	Veri yok
Peter Andersen	Senior Vice President of Global Research & Drug Discovery	no data	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: ALK B 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Katja Thalund	Project Director of Global CMC Development & Employee-elected Director	13.9yrs	DKK 350.00k	Veri yok
Lise Maerkedahl	Project Director of Global Research & Employee-elected Director	1.8yrs	DKK 270.00k	Veri yok
Jesper Hoiland	Independent Director	1.8yrs	DKK 366.00k	Veri yok
Lene Skole-Sorensen	Vice Chairman of the Board	10.9yrs	DKK 900.00k	Veri yok
Anders Hedegaard	Independent Chairman of the Board	4.8yrs	DKK 1.33m	Veri yok
Lars Holmqvist	Director	9.8yrs	DKK 446.00k	Veri yok
Gitte Aabo	Independent Director	3.8yrs	DKK 523.00k	Veri yok
Alan Main	Independent Director	2.8yrs	DKK 450.00k	Veri yok
Bertil Lindmark	Independent Director	3.8yrs	DKK 500.00k	Veri yok
Nanna Carlson	Employee Representative Director	5.8yrs	DKK 350.00k	Veri yok
Johan Smedsrud	Employee Representative Director	5.8yrs	DKK 350.00k	Veri yok

4.8yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ALK B 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/18 00:51
Gün Sonu Hisse Fiyatı	2024/12/18 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

ALK-Abelló A/S 13 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Peter Ankersen	ABG Sundal Collier
Alexandru Cogut	Bryan Garnier & Co
Jesper Ilsoe	Carnegie Investment Bank AB

ALK-Abelló Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insider exercised options to buy kr.6.3m worth of stock.

Insider recently sold kr.9.0m worth of stock

Alk-Abelló A/S Announces Executive Changes

ALK Announces Management Changes

ALK-Abelló A/S Announces Executive Changes

ALK-Abelló A/S, Annual General Meeting, Mar 23, 2023

Recent updates

ALK-Abelló A/S' (CPH:ALK B) Share Price Matching Investor Opinion

Alk-Abello A/S Approves in Europe for Treatment of Young Children

Results: ALK-Abelló A/S Exceeded Expectations And The Consensus Has Updated Its Estimates

Price target increased by 7.5% to kr.181

Third quarter 2024 earnings: EPS exceeds analyst expectations

Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?

Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

ALK Announces U.S. FDA Approval of New AccuTest Allergy Skin Testing Devices for Optimized Allergy Testing and Diagnosis

Insider exercised options to buy kr.6.3m worth of stock.

Analysts Have Made A Financial Statement On ALK-Abelló A/S' (CPH:ALK B) Second-Quarter Report

Second quarter 2024 earnings released: EPS: kr.0.90 (vs kr.0.30 in 2Q 2023)

ALK-Abelló A/S Revises Earnings Guidance for the 2024

What You Can Learn From ALK-Abelló A/S' (CPH:ALK B) P/E

Now 22% undervalued

New minor risk - Share price stability

Is ALK-Abelló (CPH:ALK B) Using Too Much Debt?

A Look At The Intrinsic Value Of ALK-Abelló A/S (CPH:ALK B)

ALK Presents Positive Phase 3 Paediatric Trial Data Offering New Hope for Children with Respiratory Allergy

Alk's European Registration Application for Itulazax for Pneumiatric Indication Accepted for Review

Now 20% undervalued

Investor sentiment improves as stock rises 17%

ALK-Abelló A/S (CPH:ALK B) Released Earnings Last Week And Analysts Lifted Their Price Target To kr.143

Price target increased by 15% to kr.143

First quarter 2024 earnings released

ALK-Abelló A/S Updates Revenue Guidance for the Year 2024

ALK-Abelló A/S' (CPH:ALK B) Share Price Matching Investor Opinion

ALK-Abelló A/S (CPH:ALK B) Shares Could Be 29% Below Their Intrinsic Value Estimate

Insider recently sold kr.9.0m worth of stock

Price target increased by 7.8% to kr.121

Full year 2023 earnings released

Alk-Abelló A/S Provides Revenue Guidance for the Year of 2024

Alk's European Registration Application for House Dust Mite Slit-Tablet in Young Children Accepts for Review

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

ALK-Abelló A/S Completes First Part of Phase 1 Trial with Peanut Slit-Tablet

With ALK-Abelló A/S (CPH:ALK B) It Looks Like You'll Get What You Pay For

ALK-Abelló A/S to Report Q2, 2024 Results on Aug 23, 2024

Price target decreased by 7.3% to kr.109

Third quarter 2023 earnings released: EPS: kr.0.50 (vs kr.0.20 in 3Q 2022)

ALK-Abelló A/S to Report Fiscal Year 2023 Results on Feb 08, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 23%

Alk-Abelló A/S Provides Earnings Guidance for the Year 2023

ALK Announces Top-Line Results from A Phase 3 Pneumiatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of Tree-Pollen-Induced Allergy Immunotherapy Tablet

ALK-Abelló A/S Narrows Revenue Guidance for the Full Year 2023

Price target decreased by 9.2% to kr.116

Investor sentiment deteriorates as stock falls 15%

New major risk - Share price stability

Alk-Abelló A/S Announces Executive Changes

Alk Announces Top-Line Results from A Phase 3 Paediatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis

ALK-Abelló A/S Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released

Price target decreased by 8.5% to kr.129

Investor sentiment deteriorates as stock falls 22%

ALK Announces Management Changes

Full year 2022 earnings: Revenues exceed analyst expectations

ALK-Abelló A/S Provides Revenue Guidance for the Full Year 2023

U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents

ALK-Abelló A/S Announces Executive Changes

ALK-Abelló A/S, Annual General Meeting, Mar 23, 2023

ALK Announces Resignation of Søren Jelert as CFO, Effective May 31, 2023

Less than half of directors are independent

Third quarter 2022 earnings released

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

Price target decreased to kr.161

Investor sentiment deteriorated over the past week

Now 21% undervalued after recent price drop

Second quarter 2022 earnings: Revenues exceed analyst expectations

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

Now 20% undervalued after recent price drop